These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32339438)

  • 1. High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution.
    Jug R; Foo WC; Jones C; Ahmadi S; Jiang XS
    Cancer Cytopathol; 2020 Aug; 128(8):563-569. PubMed ID: 32339438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.
    Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B
    Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.
    Chin PD; Zhu CY; Sajed DP; Fishbein GA; Yeh MW; Leung AM; Livhits MJ
    Endocr Pathol; 2020 Dec; 31(4):377-384. PubMed ID: 32671653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ThyroSeq overview on indeterminate thyroid nodules: An institutional experience.
    Sirotnikov S; Griffith CC; Lubin D; Zhang C; Saba NF; Li D; Kornfield A; Chen A; Shi Q
    Diagn Cytopathol; 2024 Jul; 52(7):353-361. PubMed ID: 38554032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
    Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
    Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
    Jiang XS; Harrison GP; Datto MB
    Cancer Cytopathol; 2016 Dec; 124(12):893-900. PubMed ID: 27893191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign call rate and molecular test result distribution of ThyroSeq v3.
    Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
    Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a genomic classifier on indeterminate thyroid nodules: an institutional experience.
    Abdelhakam DA; Mojica RE; Huenerberg KA; Nassar A
    J Am Soc Cytopathol; 2021; 10(2):155-163. PubMed ID: 33067175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules.
    Taye A; Gurciullo D; Miles BA; Gupta A; Owen RP; Inabnet WB; Beyda JN; Marti JL
    Surgery; 2018 Jan; 163(1):97-103. PubMed ID: 29154079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
    Selvaggi SM
    Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
    Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
    Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ThyroSeq
    Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
    Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
    Parajuli S; Jug R; Ahmadi S; Jiang XS
    Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 20. Negative Results on Thyroid Molecular Testing Decrease Rates of Surgery for Indeterminate Thyroid Nodules.
    Jug R; Parajuli S; Ahmadi S; Jiang XS
    Endocr Pathol; 2019 Jun; 30(2):134-137. PubMed ID: 30825100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.